(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens

European Journal of Pharmacology

Volumn 456, Issue 1-3, 2002, Pages 99-106

  Pertwee, Roger G ^a   Ross, Ruth A ^a   Craib, Susan J ^a   Thomas, Adèle ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cannabidiol; Cannabinoid CB1 receptor; CP55940; Drug interaction; Vas deferens, mouse; WIN55212

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; BETA,GAMMA METHYLENEADENOSINE TRIPHOSPHATE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; DIMETHYL SULFOXIDE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; METHOXAMINE; NORADRENALIN; PHENYLEPHRINE; PRAZOSIN; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; 5' ADENYLYL (BETA,GAMMA METHYLENE)DIPHOSPHONATE; 5'-ADENYLYL (BETA,GAMMA-METHYLENE)DIPHOSPHONATE; ADENOSINE TRIPHOSPHATE; CANNABINOID RECEPTOR; CYCLOHEXANOL DERIVATIVE; DRUG DERIVATIVE; DRUG RECEPTOR; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; VASOCONSTRICTOR AGENT;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; ELECTROSTIMULATION; MALE; MOUSE; MUSCLE CONTRACTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; VAS DEFERENS; ANIMAL; DOSE RESPONSE; DRUG POTENTIATION; IN VITRO STUDY; PHYSIOLOGY; SECRETION;

ADENOSINE TRIPHOSPHATE; ANIMALS; CANNABIDIOL; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; MALE; METHOXAMINE; MICE; MORPHOLINES; MUSCLE CONTRACTION; NAPHTHALENES; NOREPINEPHRINE; PHENYLEPHRINE; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; VAS DEFERENS; VASOCONSTRICTOR AGENTS;

EID: 0037027935     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02624-9     Document Type: Article

References (30)

1. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., Moriello A.S., Davis J.B., Mechoulam R., Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134:2001;845-852.
2. Breivogel C.S., Griffin G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60:2001;155-163.
3. Bylund D.B., Eikenberg D.C., Hieble J.P., Langer S.Z., Lefkowitz R.J., Minneman K.P., Molinoff P.B., Ruffolo R.R., Trendelenburg U. IV. International union of pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46:1994;121-136.
4. Colquhoun D. Lectures on Biostatistics. 1971;Oxford Univ. Press, Oxford.
5. Corbett A.D., Paterson S.J., Kosterlitz H.W. Selectivity of ligands for opioid receptors. Herz A. Opioids I. Handbook of Experimental Pharmacology. vol. 104/1:1993;645-679 Springer-Verlag, Berlin.
6. Craib S.J., Thomas A., Ross R.A., Pertwee R.G. Cannabidiol attenuates responses of the mouse isolated vas deferens to WIN55212-2 and noradrenaline. Br. J. Pharmacol. (Proc. Suppl.). 136:2002;53.
7. Hampson R.E., Deadwyler S.A. Cannabinoids, hippocampal function and memory. Life Sci. 65:1999;715-723.
8. Járai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A., Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U. S. A. 96:1999;14136-14141.
9. 9-tetrahydrocannabinol. Psychopharmacology. 33:1973;53-70.
10. 9-tetrahydrocannabinol in man. Eur. J. Pharmacol. 28:1974;172-177.
11. Pertwee R.G. The central neuropharmacology of psychotropic cannabinoids. Pharmacol. Ther. 36:1988;189-261.
12. 2 receptors. Pharmacol. Ther. 74:1997;129-180.
13. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6:1999;635-664.
14. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 63:2001;569-611.
15. Pertwee R.G. Cannabinoids and multiple sclerosis. Pharmacol. Ther. 95:2002;165-174.
16. Pertwee R.G., Griffin G. A preliminary investigation of the mechanisms underlying cannabinoid tolerance in the mouse vas deferens. Eur. J. Pharmacol. 272:1995;67-72.
17. Pertwee R.G., Ross R.A. Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fat. Acids. 66:2002;101-121.
18. 8-tetrahydrocannabinol in two isolated tissue preparations. Eur. J. Pharmacol. 315:1996;195-201.
19. 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 63:1998;PL1-PL6.
20. Poddar M.K., Dewey W.L. Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J. Pharmacol. Exp. Ther. 214:1980;63-67.
21. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:1998;413-492.
22. Ross R.A., Gibson T.M., Brockie H.C., Leslie M., Pashmi G., Craib S.J., Di Marzo V., Pertwee R.G. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br. J. Pharmacol. 132:2001;631-640.
23. Sanders J., Jackson D.M., Starmer G.A. Interactions among the cannabinoids in the antagonism of the abdominal constriction response in the mouse. Psychopharmacology. 61:1979;281-285.
24. Schlicker E., Kathman M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22:2001;565-572.
25. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
26. 2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci. 25:1979;637-654.
27. 3H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and β-adrenoceptors in mouse tissues. Br. J. Pharmacol. 130:2000;321-330.
28. von Kügelgen I., Starke K. Noradrenaline-ATP co-transmission in the sympathetic nervous system. Trends Pharmacol. Sci. 12:1991;319-324.
29. Welburn P.J., Starmer G.A., Chesher G.B., Jackson D.M. Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions. Psychopharmacology. 46:1976;83-85.
30. Whittle B.A., Guy G.W., Robson P. Prospects for new cannabis-based prescription medicines. J. Cannabis Ther. 1:2001;183-205.